Microreactor Ligand-Receptor Pairing for High-Throughput Antigen Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying T cell antigens are labor-intensive, low-throughput, and inefficient, particularly for MHC class I and class II epitopes, and lack the ability to identify antigens without prior knowledge or specific reagents, limiting their application in cancer immunotherapy and other immunological conditions.
Innovation Solution
A method involving the creation of microreactors with multiple ligands and receptors, allowing for rapid screening of thousands of antigens without a priori selection, identifying cognate pairs through frequency analysis and probability thresholds, applicable to any type of binding pairs including T cell receptors and antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods (isolating T cells, making clones, screening panels) are used to identify T cell antigens, then antigen identification can be achieved, but the process becomes extremely labor intensive and time-consuming
Solution Approach 1:
The patent segments the antigen identification process into independent parallel screening units. Instead of sequentially isolating and testing individual T cell clones, the invention uses a pooled approach where multiple T cells are screened simultaneously in a single assay, dramatically reducing the time required while maintaining identification accuracy through statistical analysis of screening results
Solution Approach 2:
The patent uses PCR amplification to generate multiple copies of T cell receptor genes from limited T cell samples. This allows the screening process to be performed on amplified DNA products rather than requiring large numbers of live T cells, reducing the time and resources needed for sample preparation while preserving the ability to identify specific antigen-reactive T cells
2Reliability
If T cell clones and tumor cell lines are established for screening, then antigen specificity can be determined, but the process becomes long and not possible for all tumor types
Solution Approach 1:
The patent develops a universal screening method that works across different tumor types without requiring establishment of tumor-specific cell lines. The pooled T cell screening approach combined with PCR amplification creates a platform that can be applied to any tumor type using the same basic protocol, significantly improving versatility while maintaining reliability through the use of tumor-informed T cells that retain antigen specificity
Solution Approach 2:
The patent extracts the essential function of T cell antigen recognition from the complex process of maintaining live T cell clones and tumor cell lines. By working with T cell receptor DNA sequences and using in silico prediction combined with pooled screening, the invention removes the requirement for establishing and maintaining complex cell culture systems, enabling application to all tumor types including those that cannot be cultured
3Adaptability or versatility
If deep sequencing and peptide binding prediction algorithms are used, then candidate epitopes can be defined without establishing tumor cell lines, but prediction algorithms are not very reliable for MHC class II restricted epitopes
Solution Approach 1:
The patent merges in silico peptide binding prediction with experimental pooled T cell screening. Rather than relying solely on computational predictions (which are unreliable for MHC class II), the invention combines algorithm-generated candidate lists with empirical validation using patient-derived T cells screened in pools, creating a hybrid approach that leverages both the speed of computation and the accuracy of experimental validation
Solution Approach 2:
The patent implements a feedback loop where initial computational predictions guide the selection of candidate epitopes for screening, and the results of pooled T cell screening feed back to refine and validate the predictions. This iterative process improves prediction accuracy by using actual patient T cell responses to confirm or correct algorithm predictions, particularly for MHC class II restricted epitopes
4Measurement precision
If MHC tetramers are synthesized to isolate reactive T cells, then potential reactive T cells can be identified, but making MHC class II tetramers is still challenging for many epitopes
Solution Approach 1:
The patent extracts the antigen specificity information from the complex MHC tetramer structure and encodes it in simplified DNA barcodes. Instead of synthesizing and handling complex MHC tetramer proteins (which is particularly difficult for MHC class II), the invention uses barcoded T cell receptors that can be amplified and screened by PCR, eliminating the manufacturing difficulties associated with tetramer production while preserving the ability to identify reactive T cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention concerns a method for identifying cognate pairs of a ligand species and a receptor species, comprising co-compartmentalising ligand species and receptor species to form a set of microreactors, each microreactor comprising at least one ligand species and preferably at least one receptor species; assaying the recognition between ligands and receptors in each microreactor and based on this assay, classifying each microreactor as positive when at least one ligand species and at least one receptor species in the microreactor recognize one with the other or negative when no ligand species and no receptor species recognize in the microreactor; identifying ligand species and receptor species contained in each positive microreactor; establishing a subset of positive microreactors containing the same receptor species; determining the probability that in a given subset of positive microreactors containing the same receptor species, the ligand species recognizing the receptor species corresponds to the most frequent co-compartmentalized ligand species; and if the determined probability is greater than a predetermined threshold, identifying as a cognate pair the receptor species and the most frequent co-compartmentalized ligand species.